Literature DB >> 34222711

Pediatric nonalcoholic fatty liver disease and the microbiome: Mechanisms contributing to pathogenesis and progression.

Nita H Salzman1,2, Jeffrey B Schwimmer3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common form of pediatric liver disease in the United States, and often associated with obesity and metabolic syndrome. NAFLD comprises a broad spectrum of liver diseases, from hepatic steatosis to steatohepatitis, fibrosis and cirrhosis. Disease progression is considered a multi-modal process of liver injury. The intestinal microbiome has been implicated in several aspects of NAFLD pathophysiology. Pediatric studies associating the intestinal microbiome with NAFLD have been limited in number and complicated by inconsistencies in study design and approach. Nevertheless, they provide support for involvement of the intestinal microbiome in NAFLD development and progression and point to common mechanisms shared by microbiome-associated inflammatory diseases with potential to inform future therapeutic intervention.

Entities:  

Year:  2021        PMID: 34222711      PMCID: PMC8248528          DOI: 10.1016/j.coemr.2021.05.003

Source DB:  PubMed          Journal:  Curr Opin Endocr Metab Res        ISSN: 2451-9650


  60 in total

Review 1.  The potter's wheel: the host's role in sculpting its microbiota.

Authors:  Charles L Bevins; Nita H Salzman
Journal:  Cell Mol Life Sci       Date:  2011-10-04       Impact factor: 9.261

2.  Steatohepatitis: a tale of two "hits"?

Authors:  C P Day; O F James
Journal:  Gastroenterology       Date:  1998-04       Impact factor: 22.682

Review 3.  Pathophysiology of Inflammatory Bowel Diseases.

Authors:  John T Chang
Journal:  N Engl J Med       Date:  2020-12-31       Impact factor: 91.245

Review 4.  Gut microbiota in human metabolic health and disease.

Authors:  Yong Fan; Oluf Pedersen
Journal:  Nat Rev Microbiol       Date:  2020-09-04       Impact factor: 60.633

Review 5.  A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier.

Authors:  Wangxin Liu; Xianliang Luo; Jun Tang; Qiufen Mo; Hao Zhong; Hui Zhang; Fengqin Feng
Journal:  Eur J Nutr       Date:  2020-11-12       Impact factor: 5.614

Review 6.  Nonalcoholic Fatty Liver Disease and the Gut Microbiome.

Authors:  Jerome Boursier; Anna Mae Diehl
Journal:  Clin Liver Dis       Date:  2015-12-24       Impact factor: 6.126

7.  Gut microbiota in adolescents and the association with fatty liver: the EPOCH study.

Authors:  Maggie A Stanislawski; Catherine A Lozupone; Brandie D Wagner; Merete Eggesbø; Marci K Sontag; Nichole M Nusbacher; Mercedes Martinez; Dana Dabelea
Journal:  Pediatr Res       Date:  2018-04-18       Impact factor: 3.756

8.  Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Marieke de Vries; Jan Westerink; Karin H A H Kaasjager; Harold W de Valk
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

Review 9.  Overview: how is alcohol metabolized by the body?

Authors:  Samir Zakhari
Journal:  Alcohol Res Health       Date:  2006

Review 10.  Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases.

Authors:  Eric Marietta; Ashutosh K Mangalam; Veena Taneja; Joseph A Murray
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.